Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/Metastatic Solid Tumors
This item is under embargo and is only visible to journalists
Please login here
Regions: Asia, Hong Kong
Keywords: Health, Medical
Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
The item has been withdrawn. If you are a journalists please contact the person that posted the item with any questions.